Kishore Kumar Hotha

Jan 8, 2025 | advancingrna.com | AR Welch |Advancing RNA |Kishore Kumar Hotha |Antony Hitchcock

Though the number of CDMOs with mRNA/RNA capabilities is increasing, many of these are better equipped for large-scale, linear mRNA development. Don't miss Advancing RNA Live on January 21st as our panel shares how mRNA and next-gen RNA modality companies need to be evaluating CDMO platforms. Attendance is free thanks to the support of Cytiva.

Dec 10, 2024 | outsourcedpharma.com | Kishore Kumar Hotha |Louis Garguilo

Guest Column | December 10, 2024 By Kishore Hotha, Dr. Hotha’s Life Sciences LLC Artificial intelligence (AI) is revolutionizing biomanufacturing by addressing critical challenges, especially in scaling production. AI platforms anticipate and resolve bottlenecks by analyzing vast data sets to detect variability in real time. For example, AI-powered monitoring systems flag deviations in synthesis or purification processes, allowing immediate corrective actions.

Dec 6, 2024 | bioprocessonline.com | Kishore Kumar Hotha |Michael Moussourakis |Jeff Phillips |Stacy Silverstein

Let Us Handle Your Buffer PreparationThermo Fisher Scientific is here to support you with the buffer preparation in your manufacturing workflow. Leaving the non-core activities to us enables you to focus on the patient therapy development. Our capabilities cover off-the-shelf products like WFI, NaOH, NaCl, or EtOH, a library of the most frequently used buffers that are made-to-order, as well as fully customized buffers.

Nov 18, 2024 | outsourcedpharma.com | Kishore Kumar Hotha |Louis Garguilo

By Kishore Hotha, Ph.D., Dr. Hotha’s Life Sciences LLC The field of therapeutic development is undergoing rapid transformation, with oligonucleotides and peptides leading the way as promising solutions for addressing a wide array of diseases. However, these advanced molecules present unique complexities that require innovative problem-solving.

May 22, 2024 | scirp.org | Kishore Kumar Hotha

1. IntroductionIn the dynamic range of pharmaceutical research, an increasing number of small to medium-sized biotech firms, many of which operate virtually, are playing a pivotal role in the early stages of drug development. These organizations typically focus not on bringing new drugs to market but on reaching key milestones such as submitting investigational new drug (IND) applications or leveraging their intellectual property (IP) for acquisition deals.